TY - JOUR AU - Di Bisceglie, Adrian M. AU - Watts, Gerald F. AU - Lavin, Philip AU - Yu, Meng AU - Bai, Ru AU - Liu, Liping PY - 2020 DA - 2020/11/12 TI - Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia JO - Lipids in Health and Disease SP - 239 VL - 19 IS - 1 AB - Reduction in elevated serum cholesterol concentrations is important in the management of individuals at risk of atherosclerotic cardiovascular disease (ASCVD), such as myocardial infarction and thrombotic stroke. Although HMGCoA reductase inhibitors (“statins”) are frequently used for this purpose, a significant proportion of patients remain at increased residual risk of ASCVD as they do not adequately address some of the associated co-morbidities such as diabetes and fatty liver disease. SN - 1476-511X UR - https://doi.org/10.1186/s12944-020-01406-4 DO - 10.1186/s12944-020-01406-4 ID - Di Bisceglie2020 ER -